Richard Brudnick to Join InflaRx Board of Directors
February 14 2019 - 8:30AM
InflaRx N.V. (Nasdaq: IFRX), an innovative
biopharmaceutical company developing anti-inflammatory therapeutics
by targeting the complement system, announced that Mr. Richard
Brudnick has been appointed as interim Non-Executive Director to
the Board of Directors of InflaRx N.V. Mr. Brudnick has substantial
experience in the biotechnology and healthcare industry and is
currently serving as Chief Business Officer and Head of Strategy
for Codiak BioSciences. He brings extensive commercial and business
development expertise to InflaRx as the Company’s pipeline
progresses towards commercialization. The confirmed appointment of
Mr. Brudnick as a Non-Executive Director of the Board is subject to
the approval at the Annual General Meeting of Shareholders in May
2019. Prior to such time, Mr. Brudnick will attend board meetings
as a non-voting observer.
“Our team is delighted to have Mr. Richard
Brudnick join our Board of Directors,” said Prof. Niels Riedemann,
MD, PhD, Chief Executive Officer and founder of InflaRx. “Mr.
Brudnick brings with him a unique business experience as InflaRx is
defining its go-to-market strategy. His in-depth knowledge of the
industry and his exceptional network will be invaluable assets to
InflaRx going forward.”
“I am excited to join the InflaRx Board of
Directors to participate in accelerating the Company’s continued
growth,” stated Mr. Brudnick. “I am impressed with the Company’s
achievements to date, and its increasing visibility in the market.
I look forward to contributing to the Company’s success as its
pipeline expands across multiple indications.”
Richard Brudnick currently serves as Chief
Business Officer and Head of Strategy for Codiak BioSciences, a
leader in the field of exosome therapeutics. Prior to joining
Codiak, Mr. Brudnick was Executive Vice President of Business
Development and Alliance Management at Bioverativ, Inc., a company
he helped found in 2016. Prior to Bioverativ’s acquisition by
Sanofi in March 2018, Mr. Brudnick led business development efforts
to build a significant pipeline in rare blood disorders, including
an acquisition, a multi-product collaboration and additional
scientific collaborations and licenses. Mr. Brudnick joined
Bioverativ at its spin-off from Biogen where, over the course of
nearly 15 years, he initiated, led and completed transactions that
now include several of the company’s marketed products and
late-stage pipeline, including Tecfidera, Spinraza and its
biosimilars joint venture with Samsung. Mr. Brudnick also was CEO
of a regional pharmaceutical distribution business, which he sold
to a strategic buyer; co-founded two companies; and was a strategy
consultant at Bain & Company.
About InflaRx N.V.:InflaRx
(Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused
on applying its proprietary anti-C5a technology to discover and
develop first-in-class, potent and specific inhibitors of C5a.
Complement C5a is a powerful inflammatory mediator involved in the
progression of a wide variety of autoimmune and other inflammatory
diseases. InflaRx was founded in 2007 and the group has offices and
subsidiaries in Jena and Munich, Germany as well as Ann Arbor, MI
and New York, NY, USA. For further information please visit
www.inflarx.com.
Contacts:Investor
RelationsInflaRx N.V.Jordan
SilversteinHead of Corporate Development and
StrategyJordan.silverstein[at]inflarx.de+1-917-837-1709
Media RelationsMC
Services AGKatja Arnold, Laurie Doyle, Andreas
Jungferinflarx[at]mc-services.eu+49-89-210 2280
FORWARD LOOKING STATEMENTSThis press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “estimate,” “believe,” “estimate,” “predict,”
“potential” or “continue” and similar expressions. Forward-looking
statements appear in a number of places throughout this release and
may include statements regarding our intentions, beliefs,
projections, outlook, analyses and current expectations concerning,
among other things, our ongoing and planned preclinical development
and clinical trials, the timing of and our ability to make
regulatory filings and obtain and maintain regulatory approvals for
our product candidates, our intellectual property position, our
ability to develop commercial functions, expectations regarding
clinical trial data, our results of operations, cash needs,
financial condition, liquidity, prospects, future transactions,
growth and strategies, the industry in which we operate, the trends
that may affect the industry or us and the risks uncertainties and
other factors described under the heading “Risk Factors” in
InflaRx’ periodic filings with the Securities and Exchange
Commission. These statements speak only as of the date of this
press release and involve known and unknown risks, uncertainties
and other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Given these risks, uncertainties
and other factors, you should not place undue reliance on these
forward-looking statements, and we assume no obligation to update
these forward-looking statements, even if new information becomes
available in the future, except as required by law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024